U.S., Sept. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07193550) titled 'A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)' on Sept. 24.
Brief Summary: To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.
Study Start Date: May 31, 2026
Study Type: INTERVENTIONAL
Condition:
Bone Sarcomas
Intervention:
DRUG: Zanzalintinib
Participants will take zanzalintinib 100mg daily by mouth
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....